
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/870627/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mouse Models in the Study of Mature B-Cell Malignancies. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a034827.	6.2	3
2	Follicular lymphoma dynamics. Advances in Immunology, 2021, 150, 43-103.	2.2	19
3	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	38
4	Mouse Models of Germinal Center Derived B-Cell Lymphomas. Frontiers in Immunology, 2021, 12, 710711.	4.8	6
5	Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis. Immunity, 2021, 54, 1807-1824.e14.	14.3	12
6	DNA damage–induced phosphorylation of CtIP at a conserved ATM/ATR site T855 promotes lymphomagenesis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	8
7	An Autochthonous Mouse Model of <i>Myd88</i> - and <i>BCL2</i> -Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. Blood Cancer Discovery, 2021, 2, 70-91.	5.0	21
8	Epigenetic Rewiring of BCR Signaling as a Novel Mechanism of Ibrutinib Resistance in ABC-DLBCL. Blood Cancer Discovery, 2021, 2, 555-558.	5.0	0
9	A Novel Autochthonous Mouse Model Serves As a Preclinical Evaluation Platform and Explores Dual BTK and BCL2 Inhibition for Activated B Cell-like Diffuse Large B Cell Lymphoma. Blood, 2021, 138, 712-712.	1.4	1
10	Tracking Immunoglobulin Repertoire and Transcriptomic Changes in Germinal Center B Cells by Single-Cell Analysis. Frontiers in Immunology, 2021, 12, 818758.	4.8	4
11	Genomic Characterization of HIV-Associated Plasmablastic Lymphoma Identifies Pervasive Mutations in the JAK〓STAT Pathway. Blood Cancer Discovery, 2020, 1, 112-125.	5.0	17
12	Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome. Journal of Experimental Medicine, 2020, 217, .	8.5	117
13	Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization. Cancer Discovery, 2020, 10, 806-821.	9.4	73
14	Genomic Characterization of HIV-Associated Plasmablastic Lymphoma Identifies Pervasive Mutations in the JAK–STAT Pathway. Blood Cancer Discovery, 2020, 1, 112-125.	5.0	40
15	Repurposing dasatinib for diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16981-16986.	7.1	21
16	Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma. Immunity, 2019, 51, 535-547.e9.	14.3	93
17	Emerging epigenetic-modulating therapies in lymphoma. Nature Reviews Clinical Oncology, 2019, 16, 494-507.	27.6	80
18	Molecular pathogenesis of germinal centerâ€derived B cell lymphomas. Immunological Reviews, 2019, 288, 240-261.	6.0	53

#	Article	IF	CITATIONS
19	Pathology and Molecular Pathogenesis of DLBCL and Related Entities. Methods in Molecular Biology, 2019, , 41-73.	0.9	2
20	Genetics of diffuse large B-cell lymphoma. Blood, 2018, 131, 2307-2319.	1.4	186
21	Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood, 2018, 131, 2454-2465.	1.4	167
22	On Statistical Modeling of Sequencing Noise in High Depth Data to Assess Tumor Evolution. Journal of Statistical Physics, 2018, 172, 143-155.	1.2	8
23	MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis. Cancer Cell, 2018, 34, 453-465.e9.	16.8	68
24	Dissecting KMT2D missense mutations in Kabuki syndrome patients. Human Molecular Genetics, 2018, 27, 3651-3668.	2.9	49
25	Targeting Histone Acetyltransferase Gene Inactivation in Diffuse Large B Cell Lymphoma. Blood, 2018, 132, 671-671.	1.4	1
26	Mutations in the RNA Splicing Factor SF3B1 Promote Transformation through MYC Stabilization. Blood, 2018, 132, 882-882.	1.4	0
27	The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. Cancer Discovery, 2017, 7, 322-337.	9.4	181
28	The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition. Nature, 2017, 546, 302-306.	27.8	64
29	Follicular lymphoma: Stateâ€ofâ€ŧheâ€art ICML workshop in Lugano 2015. Hematological Oncology, 2017, 35, 397-407.	1.7	11
30	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood, 2016, 127, 3026-3034.	1.4	168
31	Genetic drivers of NF-κB deregulation in diffuse large B-cell lymphoma. Seminars in Cancer Biology, 2016, 39, 26-31.	9.6	20
32	The genetics of nodal marginal zone lymphoma. Blood, 2016, 128, 1362-1373.	1.4	147
33	8. Diffuse large B-cell lymphoma. , 2016, , 139-170.		0
34	Chromosomal Translocations in B Cell Lymphomas. , 2015, , 157-188.		2
35	The Genetic Landscape of Diffuse Large B-Cell Lymphoma. Seminars in Hematology, 2015, 52, 67-76.	3.4	146
36	Lack of the ubiquitin-editing enzyme A20 results in loss of hematopoietic stem cell quiescence. Journal of Experimental Medicine, 2015, 212, 203-216.	8.5	45

LAURA PASQUALUCCI

#	Article	IF	CITATIONS
37	Molecular Pathogenesis of B Cell Lymphomas. , 2015, , 399-416.		0
38	An Oncogenic Role for Alternative NF-κB Signaling in DLBCL Revealed upon Deregulated BCL6 Expression. Cell Reports, 2015, 11, 715-726.	6.4	66
39	Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nature Medicine, 2015, 21, 1190-1198.	30.7	372
40	<i>BCL2</i> mutation spectrum in B ell nonâ€Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma. Hematological Oncology, 2015, 33, 23-30.	1.7	15
41	SnapShot: Diffuse Large B Cell Lymphoma. Cancer Cell, 2014, 25, 132-132.e1.	16.8	43
42	Genetics of Follicular Lymphoma Transformation. Cell Reports, 2014, 6, 130-140.	6.4	471
43	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. ELife, 2014, 3, .	6.0	43
44	MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples. BMC Systems Biology, 2013, 7, 25.	3.0	18
45	MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nature Immunology, 2013, 14, 1084-1092.	14.5	153
46	Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. Journal of Experimental Medicine, 2013, 210, 2273-2288.	8.5	255
47	SAVI: a statistical algorithm for variant frequency identification. BMC Systems Biology, 2013, 7, S2.	3.0	35
48	The genetic basis of diffuse large B-cell lymphoma. Current Opinion in Hematology, 2013, 20, 336-344.	2.5	54
49	The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development. Journal of Experimental Medicine, 2012, 209, 1537-1551.	8.5	363
50	Analysis of the coding genome of diffuse large B-cell lymphoma. Nature Genetics, 2011, 43, 830-837.	21.4	871
51	Analysis of the chronic lymphocytic leukemia coding genome: role of <i>NOTCH1</i> mutational activation. Journal of Experimental Medicine, 2011, 208, 1389-1401.	8.5	565
52	Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature, 2011, 471, 189-195.	27.8	822
53	Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma. Cancer Cell, 2011, 20, 728-740.	16.8	385
54	Alteration of BIRC3 and Multiple Other NF-κB Pathway Genes in Splenic Marginal Zone Lymphoma. Blood, 2011, 118, 264-264.	1.4	1

#	Article	IF	CITATIONS
55	Whole-Exome Sequencing Identifies Recurrent Mutations of BCOR in Acute Myeloid Leukemia with Normal Karyotype. Blood, 2011, 118, 71-71.	1.4	1
56	BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-like Diffuse Large B Cell Lymphoma. Cancer Cell, 2010, 18, 568-579.	16.8	256
57	The Genome of Chronic Lymphocytic Leukemia. Blood, 2010, 116, 51-51.	1.4	Ο
58	A20 Tumor Suppressor Deletion and BCL6 Oncogene Activation Cooperate In Deregulating B Cell Differentiation In Vivo. Blood, 2010, 116, 148-148.	1.4	0
59	MiR-28 Silencing In Germinal Center-Derived Lymphomas. Blood, 2010, 116, 703-703.	1.4	0
60	BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proceedings of the United States of America, 2009, 106, 11294-11299.	7.1	170
61	Targeted Disruption of the <i>S1P2</i> Sphingosine 1-Phosphate Receptor Gene Leads to Diffuse Large B-Cell Lymphoma Formation. Cancer Research, 2009, 69, 8686-8692.	0.9	121
62	Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature, 2009, 459, 717-721.	27.8	969
63	Mutually Exclusive Structural Alterations of BLIMP1 and BCL6 Contribute to the Pathogenesis of Activated B Cell Type Diffuse Large B Cell Lymphoma Blood, 2009, 114, 445-445.	1.4	0
64	AID is required for germinal center–derived lymphomagenesis. Nature Genetics, 2008, 40, 108-112.	21.4	340
65	Mutations in Multiple Genes Cause Deregulation of the NFkB Pathway in Diffuse Large B-Cell Lymphoma. Blood, 2008, 112, 801-801.	1.4	3
66	A Signaling Pathway Mediating Downregulation of BCL6 in Germinal Center B Cells Is Blocked by BCL6 Gene Alterations in B Cell Lymphoma. Cancer Cell, 2007, 12, 280-292.	16.8	317
67	Gene Expression Analysis of B-Cell Post Transplant Lymphoproliferative Disorders Provides Insights into Disease Biology Blood, 2007, 110, 3172-3172.	1.4	0
68	Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. Journal of Experimental Medicine, 2006, 203, 311-317.	8.5	326
69	Activation Induced Cytidine Deaminase (AID) Is Required for Germinal-Center Derived Lymphomagenesis Blood, 2006, 108, 223-223.	1.4	0
70	Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. Haematologica, 2006, 91, 1405-9.	3.5	66
71	Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell, 2005, 7, 445-455.	16.8	342
72	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood, 2005, 105, 1851-1861.	1.4	778

#	Article	IF	CITATIONS
73	Expression of the AID protein in normal and neoplastic B cells. Blood, 2004, 104, 3318-3325.	1.4	171
74	Aberrant Somatic Hypermutation Targets an Extensive Set of Genes in Diffuse Large B-Cell Lymphoma Blood, 2004, 104, 1528-1528.	1.4	2
75	Protein Expression Analysis of Chromosome 12 Candidate Genes in Chronic Lymphocytic Leukemia (B-CLL) Blood, 2004, 104, 4797-4797.	1.4	0
76	Transcriptional Deregulation of Mutated BCL6 Alleles by Loss of Negative Autoregulation in Diffuse Large B Cell Lymphoma. Annals of the New York Academy of Sciences, 2003, 987, 314-315.	3.8	3
77	Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6. Leukemia and Lymphoma, 2003, 44, S5-S12.	1.3	113
78	Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood, 2003, 101, 2914-2923.	1.4	279
79	Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature, 2001, 412, 341-346.	27.8	921
80	Analysis of a 69-kb Contiguous Genomic Sequence at a Putative Tumor Suppressor Gene Locus on Human Chromosome 6q27. DNA Sequence, 1998, 9, 189-204.	0.7	6
81	BCL-6 in Aids-Related Lymphomas: Pathogenetic and Histogenetic Implications. Leukemia and Lymphoma, 1998, 31, 39-46.	1.3	13
82	Molecular pathology of lymphoma. , 0, , 738-750.		0

Molecular pathology of lymphoma. , 0, , 738-750. 82